TRPM8 agonists as a new therapeutic strategy for chronic conditions

Learn More

TRPM8 agonists as a new therapeutic strategy for chronic conditions

Learn More

TRPM8 agonists as a new therapeutic strategy for chronic conditions

Learn More

TRPM8 agonists as a new therapeutic strategy for chronic conditions

Learn More
arrow-down-icon

Axalbion’s TRPM8 agonists offer new therapeutic approaches for chronic conditions with unmet needs

Axalbion has synthesized and examined new TRPM8 agonists, identifying two lead candidates: AX-8 and AX-10

TRPM8 icon

Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough and dry eyes, two chronic, common and debilitating disorders, with limited treatment options.

TRPM8 icon

Our molecules have a rapid onset of action and offer innovative topical treatment opportunities by normalizing abnormal cough and lacrimation reflexes and by decreasing sensory discomfort.

TRPM8 icon

Our lead compound AX-8 is at the clinical stage of development for chronic cough.

TRPM8 icon